PharmaVOICE - 
October 2009
Purchase Issue
In Every Issue
Last Word
AstraZeneca’s Dr. Larry Furlong Outlines the Company’s Lean Sigma ­Program [...]
Talent Pool
Pharmaceutical POOL Dr. Per FALK Novo Nordisk Names Clinical Research [...]
New Electronic and Web-based Applications, Sites, and Technologies Featured Briefs: [...]
What’s New
New Healthcare-related Products, Services, and Companies Featured Briefs: FDA Anticounterfeiting [...]
Sales, marketing, And R&D?Trends affecting the healthcare industry Life-Sciences Companies [...]
Milestones 15th Anniversary CenterWatch, a provider of industry news, data [...]
Letter from the Editor
Publisher Lisa Banket Editor Taren Grom Creative Director Marah Walsh [...]

Taren Grom, Editor

On The Cover

High Stakes: HITECH
The pharma industry could come out a ­winner in the new HITECH game, if ­companies can come up with the right ante. The American Recovery and Reinvestment Act (ARRA) has set forth billion to make industrywide health information exchange a reality. As part of ARRA’s provisions, the Health Information Technology for Economic and Clinical [...]

Robin Robinson


Christine Bunt: Converging on a Solution
Converging on a Solution Moving from diagnostics to pharmaceuticals, from Europe to the United States, and ultimately from big pharma to a small startup company is not for everybody. But Christine Bunt has the confidence, knowledge, and business acumen to take on any challenge, and she revels in each opportunity. In the harsh economic climate [...]

Kim Ribbink

The Reputation Matrix
The pharmaceutical industry is in some respects the victim of its own success. In fact, some public relations experts believe that the industry suffers from cognitive dissonance. “Many people are not comfortable viewing an industry responsible for developing innovative medicines as being a profit-making venture,” says Richard Salem, executive director, public affairs, at Daiichi Sankyo. [...]

Denise Myshko

A Publication Planning Update
Title VIII of FDAAA, which requires the posting of ­clinical trial data within one year from last patient last visit, puts the squeeze on ­ publication ­planners to get study results published in a very tight time frame. The Title VIII section of the Food and Drug Administration Amendments Act (FDAAA) — pronounced fa-dah by [...]

Robin Robinson